Technology ID
TAB-3626
Synthetic Genes for the Treatment of Propionic Acidemia (PA) Caused by Mutations in Propionyl-coA Carboxylase Beta (PCCB)
E-Numbers
E-175-2019-0
Lead Inventor
Venditti, Charles (National Human Genome Research Institute (NIH/NHGRI))
Co-Inventors
Chandler, Randy (National Human Genome Research Institute (NIH/NHGRI))
Applications
Therapeutics
Research Materials
Therapeutic Areas
Ophthalmology
Oncology
Infectious Disease
Endocrinology
Dental
Cardiology
Lead IC
NHGRI
This technology includes a new set of synthetic PCCB genes that can be used to treat propionic acidemia (PA) caused by propionyl-coA carboxylase beta (PCCB) mutations. The amino acid sequence of PCCB was reverse translated, using a variety of algorithms and expert input, to generate novel DNA sequences encoding PCCB (synPCCB1-5) expected to have increased expression. Next, the synPCCB sequences were cloned into a canonical adeno-associated virus (AAV) vector and tested for expression in human cells to demonstrate that the codon optimized alleles showed improved expression compared to the wild type (WT) PCCB gene. Finally, a synPCCBl AAV was pseudoserotyped with a serotype 9 capsid and used to rescue Pech-I- knock-out mice from neonatal lethality and improve their clinical and metabolic phenotypes.
Commercial Applications
These alleles will be useful to develop new therapies for propionic acidemia including AAV, genome editing and mRNA therapies.
Competitive Advantages
As these alleles are synthetic and express at higher levels than the WT PCCB allele, they have multiple advantages such as being useful for genomic medication applications, creation of vectors for genome editing, and specific nucleotide based-assays are possible for improved detection of the DNA and RNA expressed from these genes.
Licensing Contact: